Supernus bolsters Parkinson's portfolio with $400 mln deal for Adamas Pharma
Supernus Pharmaceuticals Inc said on Monday it would buy Adamas Pharmaceuticals Inc for about $400 million, to expand its roster of treatments for Parkinson's disease and reduce reliance on its top-selling epilepsy medicine.
Source: reuters.com